A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Trebananib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-3
- Sponsors Amgen
- 11 May 2017 This trial has been completed in Netherlands.
- 10 Mar 2017 This trial has been completed in Italy
- 04 Mar 2017 This trial has been completed in Greece (end date: 5 Dec 2016).